Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium.
BACKGROUND
The expression of vaccine antigens in lactic acid bacteria (LAB) is a safe and cost-effective alternative to traditional expression systems. In this study, we investigated i) the expression of Human papillomavirus type 16 (HPV-16) L1 major capsid protein in the model LAB Lactococcus lactis and ii) the ability of the resulting recombinant strain to produce either capsomer-or virus-like particles (VLPs).


CONCLUSIONS
HPV-16 L1 gene was cloned into two vectors, pCYT and pSEC, designed for controlled intra- or extracellular heterologous expression in L. lactis, respectively. The capacity of L. lactis harboring either pCYT:L1 or pSEC:L1 plasmid to accumulate L1 in the cytoplasm and supernatant samples was confirmed by Western blot assays. Electron microscopy analysis suggests that, L1 protein produced by recombinant lactococci can self-assemble into structures morphologically similar to VLPs intracellularly. The presence of conformational epitopes on the L. lactis-derived VLPs was confirmed by ELISA using an anti-HPV16 L1 capsid antigen antibody. Our results support the feasibility of using recombinant food-grade LAB, such as L. lactis, for the production of L1-based VLPs and open the possibility for the development of a new safe mucosal vector for HPV-16 prophylactic vaccination.
Cortes-Perez
Naima G
NG
Equipe Interactions des bactéries commensales et probiotiques avec l'hôte, Unité d'Ecologie et physiologie du Système Digestif, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas, France. naima.cortes-perez@jouy.inra.fr
Kharrat
Pascale
P
Langella
Philippe
P
Bermúdez-Humarán
Luis G
LG
Adv Appl Microbiol. 2004;56:1-64
15566975
Vaccine. 2007 Nov 19;25(47):8049-57
17936447
J Bacteriol. 1983 Apr;154(1):1-9
6403500
Lancet. 1998 May 9;351(9113):1375-6
9593404
Int J Infect Dis. 2007 Nov;11 Suppl 2:S10-6
18162240
J Virol. 2003 Sep;77(17):9211-20
12915537
J Mol Microbiol Biotechnol. 2008;14(1-3):80-9
17957114
Vaccine. 2008 Aug 19;26 Suppl 10:K53-61
18847557
J Bacteriol. 1993 Sep;175(18):5806-13
8376328
Nat Biotechnol. 2003 Jul;21(7):785-9
12808464
Cancer. 2008 Nov 15;113(10 Suppl):2995-3003
18980283
Microb Cell Fact. 2005 Jan 04;4(1):2
15631634
Gene. 1990 Oct 30;95(1):155-60
2123812
Lancet. 2007 Sep 8;370(9590):890-907
17826171
Nat Rev Immunol. 2006 Feb;6(2):148-58
16491139
Appl Environ Microbiol. 2006 Jan;72(1):745-52
16391114
Appl Environ Microbiol. 1996 Oct;62(10):3662-7
8837421
Appl Microbiol Biotechnol. 2005 Oct;68(6):705-17
16088349
N Engl J Med. 2002 Nov 21;347(21):1645-51
12444178
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7
18760711
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
1334560
Nat Rev Microbiol. 2008 May;6(5):349-62
18345021
Appl Environ Microbiol. 2002 Feb;68(2):917-22
11823236
FEMS Immunol Med Microbiol. 2002 Nov 15;34(3):201-8
12423772
FEMS Microbiol Lett. 2003 Dec 5;229(1):37-42
14659540
Infect Immun. 1997 Aug;65(8):3328-36
9234794
Virology. 2002 Feb 15;293(2):335-44
11886254
Virology. 1996 Sep 1;223(1):174-84
8806551
J Med Microbiol. 2004 May;53(Pt 5):427-433
15096553
J Immunol. 2005 Dec 1;175(11):7297-302
16301635